Astragalus polysaccharide composite nanoparticles and preparation method and application thereof
By preparing astragalus polysaccharide composite nanoparticles, using modified polydopamine nanomicrospheres to load astragalus polysaccharides and coat enteric-coated materials, the problems of symbiotic infection and signaling pathways were solved, and effective inhibition and treatment effects on colorectal cancer were achieved. promote.
Patent Information
- Application Number
- CN202410688962.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-30
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2044-05-30
AI Technical Summary
The prior art has failed to effectively inhibit the effect of symbiotic infection on colorectal cancer treatment, and the effect of astragalus polysaccharide on Ca2+, CAMKK2, AMPK, and mTORC signaling pathways has not been studied, affecting the treatment effect.
Using a preparation method of astragalus polysaccharide composite nanoparticles, polydopamine nanometers are polymerized under alkaline conditions by dopamine hydrochloride as raw material to form polydopamine nanometer microspheres, and their active groups are used to react with epoxychlorohydrin and carboxymethyl chitosan, and then connected The antibacterial carboxymethyl chitosan is formed to form modified polydopamine nano-microspheres, loaded with astragalus polysaccharides and coated with enteric-coated materials to produce composite nanoparticles with antibacterial and sustained release properties.
Modified polydopamine nanomicrospheres have more than 98% antibacterial effects on Staphylococcus aureus. Astragalus polysaccharide complex nanoparticles can effectively inhibit tumor cell proliferation and migration, promote autophagy, reduce inflammatory response, improve bioavailability and therapeutic effects.
Smart Images

Figure CN118649148B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and specifically relates to astragalus polysaccharide composite nanoparticles and a preparation method and application thereof. Background Art
[0002] Colorectal cancer (CRC) is one of the most common digestive tract tumors and poses a serious threat to human health. Its incidence rate is second only to esophageal cancer and gastric cancer, and its incidence and mortality rates are increasing year by year. The occurrence and development of colorectal cancer are closely related to multiple factors such as environment, genetics, diet and lifestyle. At present, the main treatment for colorectal cancer is multidisciplinary combined treatment with surgery and radiotherapy and chemotherapy as the main treatment methods. In particular, the application of traditional Chinese medicine has gradually gained attention. The traditional Chinese medicine Astragalus is based on the principle of "strengthening the body and replenishing qi", and is the main drug in a variety of anti-tumor drug compounds. Among them, Astragalus Polysaccharide (APS) is the main active ingredient of the traditional Chinese medicine Astragalus. Studies have shown that Astragalus polysaccharide can significantly inhibit the growth and invasion of colorectal cancer ectopic transplanted tumors, inhibit tumor cell growth and proliferation, and induce tumor cell death in tumor tissues. The specific mechanism of Astragalus polysaccharide in the treatment of colorectal cancer has also become a research hotspot.
[0003] At present, existing literature has explored the effects of astragalus polysaccharides on the proliferation, invasion, apoptosis and drug resistance of cisplatin-resistant colorectal cancer cells HT-29 / DDP by regulating the miR-20a / TGFBR2 molecular axis; the clinical efficacy of astragalus polysaccharides combined with interleukin-2 (IL-2) in the treatment of advanced colorectal cancer with FOLFOX4 chemotherapy; the effects of astragalus polysaccharides combined with psychological care on cellular immunity and serum inflammatory factor expression in patients after rectal cancer surgery; the effects of astragalus polysaccharides on the proliferation, apoptosis and cycle of colon cancer HT-29 cells; at the same time, the patent application with application number CN202310924290.8 used PLGA nanoparticles as a carrier to coat astragalus polysaccharides to produce anti-colorectal cancer nanoparticles, which promote the maturation of dendritic cells and activate a wide range of strong CD8 + T and CD4 + T cell response, down-regulating the expression of immune negative regulatory molecules PD-1 and TIGIT, reducing the number of Tregs cells, thereby playing an anti-colorectal cancer role, which is beneficial to improving the overall efficacy of colorectal cancer; Studies have found that Ca2+, CAMKK2, AMPK, and mTORC signaling pathways are crucial to the occurrence and development of colorectal cancer, but the above literature and patents do not mention the effect of Astragalus polysaccharides on Ca2+. 2+ , CAMKK2, AMPK, and mTORC signaling pathways.
[0004] More and more studies have shown the relationship between symbiotic infection and colorectal cancer. Colorectal cancer tissues and adjacent mucosa usually have obvious symbiotic infection. Therefore, symbiotic infection directly affects the treatment effect of colorectal cancer. In order to enhance the efficacy of astragalus polysaccharide drugs in the treatment of colorectal cancer, in addition to developing targeted preparations and improving the bioavailability of drugs, it is also crucial to further develop astragalus polysaccharide preparations that can inhibit symbiotic infection to achieve auxiliary treatment effects. Summary of the invention
[0005] The purpose of the present invention is to address the deficiencies of the prior art and provide an astragalus polysaccharide composite nanoparticle and a preparation method and application thereof.
[0006] The technical solution adopted by the present invention to achieve the above-mentioned purpose is:
[0007] A method for preparing astragalus polysaccharide composite nanoparticles comprises the following steps:
[0008] S1. Add dopamine hydrochloride to an ethanol aqueous solution, adjust the pH to 7.5-8.0 with an alkaline aqueous solution, stir and react at 30-40° C. for 10-15 hours. After the reaction is completed, centrifuge and remove the supernatant. Wash the precipitate with ethanol and water in turn, and dry to obtain polydopamine nanoparticles;
[0009] S2, add polydopamine nanoparticles to ethanol, disperse evenly, add epichlorohydrin dropwise, react at 50-60°C for 4-6h, then add 3-5wt% carboxymethyl chitosan aqueous solution and triethylamine, heat to 70-80°C, react for 8-10h, after the reaction is completed, cool to room temperature, centrifuge, remove supernatant, wash the precipitate with ethanol and water in turn, and dry to obtain modified polydopamine nanoparticles;
[0010] S3, dissolving astragalus polysaccharide in a phosphate buffer solution, adding modified polydopamine nanoparticles, stirring at room temperature for 24 hours, centrifuging, removing the supernatant, washing the precipitate with a phosphate buffer solution, and freeze-drying to obtain modified polydopamine nanoparticles loaded with astragalus polysaccharide;
[0011] S4. Dissolve the modified polydopamine nanospheres loaded with astragalus polysaccharide in acetone, add enteric material and emulsifier, stir for 24 hours at room temperature, centrifuge, remove the supernatant, wash the precipitate with acetone, and freeze-dry to obtain composite nanoparticles.
[0012] Furthermore, in step S1, the concentration of dopamine hydrochloride in the ethanol aqueous solution is 3-5 mg / mL; the mass ratio of ethanol to water is 1:4-6; and the alkaline aqueous solution is a 20-30 wt % ammonia aqueous solution.
[0013] Furthermore, in step S2, the concentration of polydopamine nanospheres in ethanol is 80-100 mg / mL; the mass ratio of the polydopamine nanospheres, epichlorohydrin, carboxymethyl chitosan, and triethylamine is 1:0.2-0.3:0.4-0.5:0.2-0.3.
[0014] Furthermore, in step S3, the concentration of astragalus polysaccharide in the phosphate buffer solution is 0.4-0.6 mg / mL; the concentration of modified polydopamine nanoparticles is 1-2 mg / mL; and the pH value of the phosphate buffer solution is 7.4.
[0015] Furthermore, in step S4, the concentration of the modified polydopamine nanoparticles loaded with astragalus polysaccharide in acetone is 50-60 mg / mL; the mass ratio of the modified polydopamine nanoparticles loaded with astragalus polysaccharide and the enteric material is 1:1.5-2; the amount of the emulsifier is 2-3% of the total mass of the modified polydopamine nanoparticles loaded with astragalus polysaccharide and the enteric material; the enteric material is composed of acrylic resin II and acrylic resin III in a mass ratio of 1:2-3; and the emulsifier is polyvinyl alcohol.
[0016] The present invention also provides an astragalus polysaccharide composite nanoparticle, which is prepared by the above-mentioned astragalus polysaccharide composite nanoparticle preparation method.
[0017] The present invention also provides the use of astragalus polysaccharide composite nanoparticles in the preparation of a drug for treating colorectal cancer, wherein the drug comprises the above-mentioned astragalus polysaccharide composite nanoparticles; the drug inhibits the expression of P62, P70s6k, Beclin-1, and m-TOR proteins, promotes the expression of CAMKK2 and AMPK proteins, reduces the expression levels of P62, P70s6k, Beclin-1, and mTORC protein mRNA, and increases the expression levels of CAMKK2 and AMPK protein mRNA, thereby exerting an anti-colorectal cancer effect.
[0018] The present invention has the following beneficial effects:
[0019] In order to improve the therapeutic effect of astragalus polysaccharide on colorectal cancer, the invention prepares astragalus polysaccharide into a composite nanoparticle preparation; the invention first uses dopamine hydrochloride as a raw material, polymerizes under alkaline conditions to form polydopamine nano-microspheres, and then uses the active group amino group of the polydopamine nano-microspheres to react with epichlorohydrin and carboxymethyl chitosan to obtain modified polydopamine nano-microspheres, and the surface of the prepared modified polydopamine nano-microspheres is grafted with carboxymethyl chitosan with antibacterial effect. The antibacterial experiment of the modified polydopamine nano-microspheres shows that when the concentration of the modified polydopamine nano-microspheres is 250 μg / mL, the modified polydopamine nano-microspheres have an antibacterial effect on golden yellow. The antibacterial effect on Staphylococcus aureus reaches more than 98%, indicating that the modified polydopamine nano-microspheres have good antibacterial properties. Using them to load astragalus polysaccharides can help inhibit symbiotic bacteria infection, thereby improving the therapeutic effect of astragalus polysaccharides against colorectal cancer. The present invention loads astragalus polysaccharides on modified polydopamine nano-microspheres, and further uses enteric materials for coating to obtain astragalus polysaccharide composite nanoparticles. The obtained astragalus polysaccharide composite nanoparticles have good sustained-release properties, can reach the intestine to release astragalus polysaccharides, avoid gastric juice from destroying the drug, and help improve the bioavailability of astragalus polysaccharides and the overall therapeutic effect of colorectal cancer.
[0020] The present invention shows through cell level experiments that the astragalus polysaccharide composite nanoparticles can effectively inhibit the proliferation activity of MC38 cells, inhibit the migration ability of MC38 cells, and promote the autophagy of MC38 cells; animal experiments show that the astragalus polysaccharide composite nanoparticles can inhibit the growth of mouse tumors, promote the autophagy and apoptosis of tumor tissue cells in tumor-bearing mice, reduce the malignant proliferation of tumor tissues in tumor-bearing mice, reduce the expression levels of pro-inflammatory factors TNFα, IL-1β, IL-17, IL-6 and TGF-β, reduce the inflammatory response, and have a small degree of liver damage to tumor-bearing mice; and promote the expression of CAMKK2 and AMPK proteins by inhibiting the expression of P62, P70s6k, Beclin-1 and m-TOR proteins, reduce the expression levels of P62, P70s6k, Beclin-1 and mTORC protein mRNA, and increase the expression levels of CAMKK2 and AMPK protein mRNA, thereby playing an anti-colorectal cancer role. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 This is the antibacterial result diagram of modified polydopamine nanoparticles;
[0022] Figure 2 This is the in vitro release curve of Astragalus polysaccharide composite nanoparticles;
[0023] Figure 3 The effects of different gradient concentrations of Astragalus polysaccharide composite nanoparticles and treatment time on the proliferation activity of MC38 cells;
[0024] Figure 4The effects of different drug groups on MC38 cell migration;
[0025] Figure 5 The effects of different drug groups on autophagy of MC38 cells (AO staining);
[0026] Figure 6 The effects of different drug groups on autophagy of MC38 cells (MDC staining);
[0027] Figure 7 The changes of body weight and tumor volume of mice in different drug groups after tumor bearing;
[0028] Figure 8 The pathological effects of different drug groups on tumor tissue, liver, and spleen of tumor-bearing mice;
[0029] Fig. 9 The effects of different drug groups on serum biochemical indices of tumor-bearing mice;
[0030] Fig.10 The effects of different drug groups on serum cytokine levels in tumor-bearing mice;
[0031] Fig.11 The effects of different drug groups on autophagy of tumor tissue cells in tumor-bearing mice;
[0032] Fig.12 The effect of different drug groups on the expression of autophagy-related proteins in tumor tissues of tumor-bearing mice;
[0033] Fig.13 The effects of different drug groups on the expression of autophagy-related proteins and signal pathway-related proteins in tumor tissues of tumor-bearing mice;
[0034] Fig.14 The effects of different drug groups on the mRNA expression of autophagy-related proteins and signal pathway-related proteins in tumor tissues of tumor-bearing mice;
[0035] Fig.15 This is the effect of different drug groups on the apoptosis level of tumor tissue cells in tumor-bearing mice. DETAILED DESCRIPTION
[0036] The following will be combined with the embodiments of the present application to clearly and completely describe the technical solutions in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.
[0037] In the technical scheme of the present invention, the raw materials and reagents used in the following embodiments, comparative examples and related experiments are all common commercially available products, and the related detection methods involved are all conventional technical detections, including carboxymethyl chitosan (MW = 8.5kDa, deacetylation degree = 90%, carboxymethylation degree = 85%), pharmaceutical grade; astragalus polysaccharide CAS No. 89250-26-0; dopamine hydrochloride CAS No. 62-31-7; epichlorohydrin CAS No. 106-89-8; fluorouracil CAS No. 51-21-8; AMPK inhibitor Dorsomorphin (Compound C) CAS No. 866405-64-3; in the statistical analysis results *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
[0038] Example 1
[0039] A method for preparing astragalus polysaccharide composite nanoparticles comprises the following steps:
[0040] S1. Add dopamine hydrochloride to an ethanol aqueous solution, adjust the pH to 8.0 with an alkaline aqueous solution, stir and react at 40°C for 15 hours, centrifuge after the reaction is completed, remove the supernatant, wash the precipitate with ethanol and water in turn, and dry to obtain polydopamine nanospheres; the concentration of dopamine hydrochloride in the ethanol aqueous solution is 4 mg / mL; the mass ratio of ethanol to water is 1:6; the alkaline aqueous solution is a 30wt% ammonia aqueous solution;
[0041] S2, add polydopamine nanospheres to ethanol, disperse them evenly, add epichlorohydrin dropwise, react at 50°C for 6h, then add 5wt% carboxymethyl chitosan aqueous solution and triethylamine, heat to 80°C, react for 8h, cool to room temperature after the reaction is completed, centrifuge, remove the supernatant, wash the precipitate with ethanol and water in turn, and dry to obtain modified polydopamine nanospheres; the concentration of polydopamine nanospheres in ethanol is 100mg / mL; the mass ratio of polydopamine nanospheres, epichlorohydrin, carboxymethyl chitosan, and triethylamine is 1:0.3:0.5:0.3;
[0042] S3, dissolving astragalus polysaccharide in phosphate buffer solution, adding modified polydopamine nanospheres, stirring at room temperature for 24 hours, centrifuging, removing the supernatant, washing the precipitate with phosphate buffer solution, and freeze-drying to obtain modified polydopamine nanospheres loaded with astragalus polysaccharide; the concentration of astragalus polysaccharide in the phosphate buffer solution is 0.6 mg / mL; the concentration of modified polydopamine nanospheres is 2 mg / mL; the pH value of the phosphate buffer solution is 7.4;
[0043] S4. Dissolve the modified polydopamine nanoparticles loaded with astragalus polysaccharide in acetone, add enteric material and emulsifier, stir at room temperature for 24 hours, centrifuge, remove the supernatant, wash the precipitate with acetone, and freeze-dry to obtain composite nanoparticles; the concentration of the modified polydopamine nanoparticles loaded with astragalus polysaccharide in acetone is 60 mg / mL; the mass ratio of the modified polydopamine nanoparticles loaded with astragalus polysaccharide and the enteric material is 1:2; the amount of emulsifier is 2% of the total mass of the modified polydopamine nanoparticles loaded with astragalus polysaccharide and the enteric material; the enteric material is composed of acrylic resin II and acrylic resin III in a mass ratio of 1:3; the emulsifier is polyvinyl alcohol.
[0044] Example 2
[0045] A method for preparing astragalus polysaccharide composite nanoparticles comprises the following steps:
[0046] S1. Add dopamine hydrochloride to an ethanol aqueous solution, adjust the pH to 7.5 with an alkaline aqueous solution, stir and react at 35°C for 10 hours, centrifuge after the reaction is completed, remove the supernatant, wash the precipitate with ethanol and water in turn, and dry to obtain polydopamine nanospheres; the concentration of dopamine hydrochloride in the ethanol aqueous solution is 5 mg / mL; the mass ratio of ethanol to water is 1:5; the alkaline aqueous solution is a 20wt% ammonia aqueous solution;
[0047] S2, add polydopamine nanospheres to ethanol, disperse evenly, add epichlorohydrin dropwise, react at 60°C for 4h, then add 3wt% carboxymethyl chitosan aqueous solution and triethylamine, heat to 70°C, react for 10h, cool to room temperature after the reaction, centrifuge, remove supernatant, wash the precipitate with ethanol and water in turn, and dry to obtain modified polydopamine nanospheres; the concentration of polydopamine nanospheres in ethanol is 80mg / mL; the mass ratio of polydopamine nanospheres, epichlorohydrin, carboxymethyl chitosan, and triethylamine is 1:0.2:0.4:0.2;
[0048] S3, dissolving astragalus polysaccharide in phosphate buffer solution, adding modified polydopamine nanospheres, stirring at room temperature for 24 hours, centrifuging, removing the supernatant, washing the precipitate with phosphate buffer solution, and freeze-drying to obtain modified polydopamine nanospheres loaded with astragalus polysaccharide; the concentration of astragalus polysaccharide in the phosphate buffer solution is 0.4 mg / mL; the concentration of modified polydopamine nanospheres is 1 mg / mL; the pH value of the phosphate buffer solution is 7.4;
[0049] S4. Dissolve the modified polydopamine nanoparticles loaded with astragalus polysaccharide in acetone, add enteric material and emulsifier, stir at room temperature for 24 hours, centrifuge, remove the supernatant, wash the precipitate with acetone, and freeze-dry to obtain composite nanoparticles; the concentration of the modified polydopamine nanoparticles loaded with astragalus polysaccharide in acetone is 50 mg / mL; the mass ratio of the modified polydopamine nanoparticles loaded with astragalus polysaccharide and the enteric material is 1:1.5; the amount of emulsifier is 3% of the total mass of the modified polydopamine nanoparticles loaded with astragalus polysaccharide and the enteric material; the enteric material is composed of acrylic resin II and acrylic resin III in a mass ratio of 1:2; the emulsifier is polyvinyl alcohol.
[0050] Example 3
[0051] A method for preparing astragalus polysaccharide composite nanoparticles comprises the following steps:
[0052] S1. Add dopamine hydrochloride to an ethanol aqueous solution, adjust the pH to 7.8 with an alkaline aqueous solution, stir and react at 30°C for 13 hours, centrifuge after the reaction is completed, remove the supernatant, wash the precipitate with ethanol and water in turn, and dry to obtain polydopamine nanospheres; the concentration of dopamine hydrochloride in the ethanol aqueous solution is 3 mg / mL; the mass ratio of ethanol to water is 1:4; the alkaline aqueous solution is a 25wt% ammonia aqueous solution;
[0053] S2, add polydopamine nanospheres to ethanol, disperse evenly, add epichlorohydrin dropwise, react at 55°C for 5h, then add 4wt% carboxymethyl chitosan aqueous solution and triethylamine, heat to 75°C, react for 9h, cool to room temperature after the reaction, centrifuge, remove supernatant, wash the precipitate with ethanol and water in turn, and dry to obtain modified polydopamine nanospheres; the concentration of polydopamine nanospheres in ethanol is 90mg / mL; the mass ratio of polydopamine nanospheres, epichlorohydrin, carboxymethyl chitosan, and triethylamine is 1:0.25:0.45:0.3;
[0054] S3, dissolving astragalus polysaccharide in phosphate buffer solution, adding modified polydopamine nanospheres, stirring at room temperature for 24 hours, centrifuging, removing the supernatant, washing the precipitate with phosphate buffer solution, and freeze-drying to obtain modified polydopamine nanospheres loaded with astragalus polysaccharide; the concentration of astragalus polysaccharide in the phosphate buffer solution is 0.5 mg / mL; the concentration of modified polydopamine nanospheres is 1.5 mg / mL; the pH value of the phosphate buffer solution is 7.4;
[0055] S4. Dissolve the modified polydopamine nanoparticles loaded with astragalus polysaccharide in acetone, add enteric material and emulsifier, stir at room temperature for 24 hours, centrifuge, remove the supernatant, wash the precipitate with acetone, and freeze-dry to obtain composite nanoparticles; the concentration of the modified polydopamine nanoparticles loaded with astragalus polysaccharide in acetone is 55 mg / mL; the mass ratio of the modified polydopamine nanoparticles loaded with astragalus polysaccharide and the enteric material is 1:1.8; the amount of the emulsifier is 2.5% of the total mass of the modified polydopamine nanoparticles loaded with astragalus polysaccharide and the enteric material; the enteric material is composed of acrylic resin II and acrylic resin III in a mass ratio of 1:2.5; the emulsifier is polyvinyl alcohol.
[0056] 1. Testing the antibacterial properties of modified polydopamine nanospheres
[0057] The antibacterial properties of the modified polydopamine nanoparticles prepared in Examples 1-3 against Staphylococcus aureus were tested. The polydopamine nanoparticles were used as a control. Nanoparticles of different concentrations (0 μg / mL, 50 μg / mL, 100 μg / mL, 150 μg / mL, 250 μg / mL) were mixed with 100 μL, 2×10 6 CFU / mL of bacterial solution were mixed evenly, incubated at 37 and 42 °C for 2 h at 110 rpm, taken out, diluted, and plated. The results were as follows: Figure 1 As shown in the figure, with the increase of the concentration of modified polydopamine nanomicrospheres, the antibacterial rate against Staphylococcus aureus also gradually increased, and the two were positively correlated. When the concentration of modified polydopamine nanomicrospheres was 250 μg / mL, the antibacterial rate of the modified polydopamine nanomicrospheres of Examples 1-3 against Staphylococcus aureus reached more than 98%, which was much better than the control polydopamine nanomicrospheres, indicating that the modified polydopamine nanomicrospheres prepared by the present invention have good antibacterial properties and can help inhibit symbiotic bacteria infection.
[0058] 2. Testing the sustained release performance of composite nanoparticles
[0059] The composite nanoparticles of Examples 1-3 were prepared into 1 mg / mL solutions and released in artificial intestinal fluid. The content of astragalus polysaccharide in the released solution was determined by phenol-sulfuric acid method on days 1, 2, 3, 4, 5, 6, and 7. The in vitro release curves of the composite nanoparticles are shown in FIG. Figure 2 As shown, on the 7th day, the cumulative release rate of astragalus polysaccharides in the composite nanoparticles of Examples 1-3 reached more than 80%, indicating that the composite nanoparticles prepared by the present invention have good sustained-release properties in artificial intestinal fluid, can achieve targeted sustained-release administration of astragalus polysaccharides, and help improve its efficacy in treating colorectal cancer and the bioavailability of the drug.
[0060] 3. Cell and animal experiments on astragalus polysaccharide composite nanoparticles
[0061] Cell culture: Mouse colon cancer cell MC38 was cultured in DMEM high-glucose medium containing 10% fetal bovine serum and 1% penicillin-streptomycin double antibody, in an incubator at 37°C, 5% CO2 and saturated humidity, and passaged when grown to about 90%; logarithmic phase colon cancer MC38 cells were taken, washed with PBS buffer, and culture medium was added to terminate the digestion after trypsin digestion, and the MC38 cells were transferred to a 10mL centrifuge tube, centrifuged at 1500r / min for 5min, and then the cells were suspended with culture medium, and the cells were inoculated into 12-well plates after counting. When the cell fusion reached 40-50%, the cells were divided into blank group (Control), APS group, autophagy agonist rapamycin group (RAPA), APS and autophagy agonist rapamycin group (APS+RAPA), calcium ion chelator group (BAPTA-AM), APS and calcium ion chelator group (APS+BAPTA-AM).
[0062] Animal culture: 120 SPF male BALB / c nude mice aged 6-8 weeks, weighing (20±2) g, were purchased from Huaxing Experimental Animal Farm in Huiji District, Zhengzhou City. They were divided into model control group (Model), APS group, 5-FU group, APS and 5-FU group (APS+5-FU), Compound C group, and APS+Compound C group. The cell concentration was 2×10 7 MC38 cell suspension with a concentration of 1 cell / mL was injected ectopically into the subcutaneous tissue of the right armpit of mice (0.2 mL / mouse).
[0063] From the day of MC38 cell inoculation, the Model group was given an intraperitoneal injection of normal saline 200 μL / time / animal / day; the APS group was given an intraperitoneal injection of astragalus polysaccharide composite nanoparticles 5 mg / mL, 200 μL / time / animal / day; the 5-FU group was given an intraperitoneal injection of fluorouracil 2 mg / mL, 200 μL / time / animal / day; the APS+5-FU group was given an intraperitoneal injection of astragalus polysaccharide composite nanoparticles 5 mg / kg and fluorouracil 20 mg / kg; the Compound C group was given an intraperitoneal injection of Compound C 10 mg / kg; the APS+Compound C group was given an intraperitoneal injection of astragalus polysaccharide composite nanoparticles 5 mg / kg and Compound C 10 mg / kg; the drug was administered continuously for three weeks, and the general condition, body weight, and survival period of the nude mice were observed and recorded every day. The tumor growth of the mice was observed with a live imaging device every week, images were taken, and the tumor formation was recorded. The long diameter (a) and short diameter (b) of the tumor were measured, and the tumor volume was calculated according to the volume formula V=1 / 2ab2. After 31 days, all the nude mice were killed, the tumor tissue was dissected out, the gross specimens were observed, the tumor mass was weighed, and the tumor volume was compared; part of the tumor tissue was fixed, paraffin sections were made, HE staining and immunohistochemistry were performed, and the pathological tissue conditions under the microscope were observed.
[0064] 1. Effect of Astragalus polysaccharide composite nanoparticles on the proliferation activity of MC38 cells
[0065] The MC38 cells in the APS group were treated with various concentrations of astragalus polysaccharide composite nanoparticles (0 μg / mL, 200 μg / mL, 400 μg / mL, 600 μg / mL, 800 μg / mL, 1000 μg / mL, 1200 μg / mL, 1400 μg / mL, and 1600 μg / mL) for 24 h, 48 h, and 72 h, and the appropriate drug concentration and action time of astragalus polysaccharide composite nanoparticles for cell intervention experiments were screened by CCK8 experiment. The results are as follows: Figure 3 As shown in the data, the initial low concentration of 200 μg / mL astragalus polysaccharide composite nanoparticles had no obvious inhibitory effect in the early stage of intervention (P>0.05), and the rest showed general inhibition (P<0.05), and its inhibitory effect was time- and concentration-dependent. Treatment with 1600 μg / mL astragalus polysaccharide composite nanoparticles for 24h, 48h, and 72h could completely inhibit the survival of MC38 cells, and cell experiments were carried out using 1600 μg / mL astragalus polysaccharide composite nanoparticles.
[0066] 2. Effect of Astragalus polysaccharide composite nanoparticles on MC38 cell migration
[0067] The scratch test was used to detect the effects of astragalus polysaccharide composite nanoparticles and other drugs on the migration ability of MC38 cells. The control group did not use any drugs, and the drugs were added after 24 hours of cell culture. The APS group was added with 100 μL astragalus polysaccharide composite nanoparticles, the RAPA group was added with 3 nM rapamycin, the APS+RAPA group was added with 3 nM rapamycin and 100 μL astragalus polysaccharide composite nanoparticles, the BAPTA-AM group was added with 10 μM calcium ion chelator, and the APS+BAPTA-AM group was added with 10 μM calcium ion chelator and 100 μL astragalus polysaccharide composite nanoparticles; the results are shown in Figure 3. Figure 4 As shown, Figure 4 a is the image of cell scratch observation under microscope (40x), Figure 4 b is the result of statistical analysis. Compared with the cells in the Control group, the cell migration rates of the APS group, RAPA group, and APS+RAPA group were significantly reduced, and the cell migration rates of the BAPTA-AM group and APS+BAPTA-AM group were significantly increased, indicating that Astragalus polysaccharide composite nanoparticles can effectively inhibit the migration ability of MC38 cells, and the inhibitory effect is the strongest.
[0068] 3. AO staining combined with scratch test to observe the effect of astragalus polysaccharide composite nanoparticles on MC38 cell autophagy
[0069] The results of AO staining combined with scratch test are as follows Figure 5 As shown, Figure 5 a is the image observed under AO staining microscope (40x), Figure 5 b is the result of statistical analysis. Compared with the Control group, the intensity and number of green punctate fluorescence in the cells of the APS group increased significantly. After the combined use of the autophagy agonist RAPA, the intensity and number of intracellular green punctate fluorescence increased significantly compared with the use of Astragalus polysaccharide composite nanoparticles alone. The green fluorescence intensity and number of the BAPTA-AM group and the APS+BAPTA-AM group were significantly decreased compared with the APS group, indicating that Astragalus polysaccharide composite nanoparticles can effectively promote autophagy in MC38 cells.
[0070] 4. MDC staining combined with scratch test to detect the effect of astragalus polysaccharide composite nanoparticles on MC38 cell autophagy
[0071] The results of MDC staining combined with scratch test are as follows Figure 6 As shown, Figure 6 a is the image observed under MDC staining microscope (40x), Figure 6 b is the result of statistical analysis. Compared with the Control group, the intensity and number of green punctate fluorescence in the cells of the APS group were significantly increased. After the combined use of the autophagy agonist RAPA, the intensity and number of intracellular green punctate fluorescence were significantly increased compared with the use of Astragalus polysaccharide composite nanoparticles alone. After the use of the calcium chelator BAPTA-AM, the green fluorescence intensity and number of the BAPTA-AM group and the APS+BAPTA-AM group were significantly decreased compared with the APS group, which also shows that Astragalus polysaccharide composite nanoparticles can effectively promote autophagy in MC38 cells.
[0072] 5. Changes in body weight and tumor size of mice after tumor implantation
[0073] The body weight change curve and tumor weight change curve of MC38 tumor-bearing mice after intervention with different drug groups are shown in Figure 2. Figure 7 As shown, Figure 7 a is the weight change curve, Figure 7 b is the curve of tumor weight change. Compared with the Model group, the tumor growth of mice in the APS group was relatively slow; the weight loss of mice was also relatively slow, and cachexia was relatively not obvious; while the tumors of mice in the Compound C group and the APS+Compound C group grew rapidly, and the proportion of tumor weight to mouse body weight also increased significantly, indicating that Astragalus polysaccharide composite nanoparticles can effectively inhibit the growth of mouse tumors.
[0074] 6. Effects of Astragalus Polysaccharide Composite Nanoparticles on Tumor Tissue, Liver and Spleen Pathology in Tumor-bearing Mice
[0075] After the mice were killed, the tumor tissues, livers, and spleens of the mice were obtained and fixed, dehydrated, sliced, dried, dewaxed, and HE (eosin-hematoxylin) stained. The effects of astragalus polysaccharide composite nanoparticles on the pathology of tumor tissues, livers, and spleens of tumor-bearing mice in each group were observed under HE microscope. The results are as follows: Figure 8 As shown in (630x), the CRC tissue in the Model group had a tight texture, and the tumor cells were highly malignant and had obvious heterogeneity, without obvious inflammatory cell infiltration and intratumoral hemorrhage. The CRC tissue in the 5-FU group, APS group, Compound C group, and APS plus Compound C group had a slightly loose texture, with visible necrotic foci and varying degrees of inflammatory cell infiltration. Compared with the Model group, the liver damage in the APS group was less severe, the malignant proliferation of the tumor tissue was less severe, the necrotic area was slightly larger, the germinal centers of the spleen were more numerous, and the immunity of the mice showed a positive trend of improvement. The liver damage in the Compound C group was lighter than that in the 5-FU group, but still heavier than that in the APS group. The livers of the Compound C group and the 5-FU group also showed varying degrees of edema, degeneration and necrosis. This indicates that the Astragalus polysaccharide composite nanoparticles can effectively reduce the malignant proliferation of tumor tissue in tumor-bearing mice and cause less liver damage to tumor-bearing mice.
[0076] 7. Effects of Astragalus Polysaccharide Composite Nanoparticles on the Levels of Serum Biochemical Indicators ALT, AST, CR, and UA in Tumor-Bearing Mice
[0077] The serum biochemical indicators ALT, AST, CR, and UA of tumor-bearing mice were tested. Fig. 9 As shown in the data, compared with the Model group, the liver and kidney functions of the APS group were relatively stable, and the ALT, AST, CR, and UA indicators were reduced, while the liver and kidney function indicators of the Compound C group were significantly increased, and the liver and kidney function damage was greater. Compared with the Model group, the liver and kidney function indicators of the APS+Compound C group increased less significantly than those of Compound C alone, which also shows that the Astragalus polysaccharide composite nanoparticles cause less liver damage to tumor-bearing mice.
[0078] 8. Effect of Astragalus Polysaccharide Composite Nanoparticles on Serum Cytokine Levels in Tumor-bearing Mice
[0079] The expression levels of serum cytokines TNFα, IL-1β, IL-17, IL-6, and TGF-β in tumor-bearing mice were detected by ELISA. Fig.10As shown in the data, compared with the Model group, the TNFα level in the APS group was significantly decreased, and the expression levels of proinflammatory factors IL-1β, IL-17, IL-6 and TGF-β were all reduced, while the relevant indicators of the Compound C group were significantly increased. Except for TNFα, which was not significantly decreased in the APS+Compound C group, the other indicators were significantly increased. Compared with the APS group, the levels of all cytokines in the Compound C group were significantly increased, indicating that Astragalus polysaccharide composite nanoparticles can effectively reduce the inflammatory response and achieve the treatment of colorectal cancer in mice.
[0080] 9. Effect of Astragalus Polysaccharide Composite Nanoparticles on Autophagy of Tumor Tissue Cells in Tumor-bearing Mice
[0081] Tumor tissue was selected, cut into small pieces of 0.5-1 mm3, immersed in 2.5% glutaraldehyde for pre-fixation, then rinsed with 1 mol / L phosphate buffer (PBS), post-fixed with 1% osmium acid, rinsed with PBS, and dehydrated with acetone gradient at room temperature. Then, the thyroid tissue specimens with good penetration of the embedding agent were picked out for ultrathin sectioning, double staining with citric acid and lead uranyl acetate, and finally observed under a transmission electron microscope and photographed to record the results.
[0082] The results are as follows Fig.11 As shown, Fig.11 AF in a are the autophagosome structures of tumor tissues of tumor-bearing mice in different drug groups under microscope (transmission electron microscope, ×20000), A is APS group, B is APS+5-FU group, C is APS+Compound C group, D is 5-FU group, E is Model group, and F is Compound C group. Autophagosome-autophagosome, autopolysosome-autophagolysosome, M-mitochondria, N-nucleus, ER-endoplasmic reticulum, Avi-initial autophagic vesicle, Avd-degraded autophagic vesicle. It can be seen that in the Model group (E), the cell structure is disordered, the nucleus is swollen, and the nuclear-cytoplasmic ratio is seriously abnormal. Some mitochondria in the cytoplasm are numerous, and some are swollen and have broken cristae. Lysosomes can be seen, but autophagosome structures are rare. In the APS group (A), the cell structure is highly polar, the nucleus is relatively regular or slightly deformed, the nuclear-cytoplasmic ratio is slightly abnormal, and more autophagosome structures can be seen under microscope in the cytoplasm. In group C (F), the cell structure was disordered, the nucleus was deformed and obviously swollen, the nuclear-cytoplasmic ratio was seriously abnormal, a large number of vacuoles were seen in the cytoplasm, the endoplasmic reticulum (ER) was swollen, and the autophagosome structure was rare; in group APS+5-FU (C), the cell structure was disordered, the nucleus was atrophied or deformed, the nuclear-cytoplasmic ratio was imbalanced, and a small number of autophagosome structures were seen in the cytoplasm; Fig.11b is the result of statistical analysis. Compared with the Model group, the number of autophagosomes in the APS group was significantly higher; the number of autophagosomes in the Compound C group was smaller. Compared with the 5-FU group (Group F), the number of autophagosome structures in the APS group (Group A) was significantly increased, indicating that Astragalus polysaccharide composite nanoparticles can effectively promote autophagy of tumor tissue cells in tumor-bearing mice.
[0083] 10. Effect of Astragalus Polysaccharide Composite Nanoparticles on the Expression of Autophagy-related Proteins in Tumor Tissues of Tumor-bearing Mice
[0084] By performing IHC tests on paraffin samples of tumor tissues from tumor-bearing mice, it was found that the expression levels of autophagy-related proteins were significantly different between the different intervention groups; the results are as follows Fig.12 As shown in Figure 2, in the expression of autophagy upstream and downstream proteins ( Fig.12 a), compared with the Model group, the expression levels of P62, P70s6k, and Beclin-1 proteins in the APS group were significantly reduced, indicating that APS can effectively inhibit the expression of P62, P70s6k, and Beclin-1 proteins; in the expression of autophagy pathway-related proteins ( Fig.12 b), compared with the Model group, the expression levels of CAMKK2 and AMPK proteins in the APS group were significantly increased, and the expression level of m-TOR protein was significantly decreased. There was no statistical difference in the expression of CAMKK2 and m-TOR proteins between the Compound C group and the Model group, while the expression of AMPK protein was significantly decreased, indicating that astragalus polysaccharide composite nanoparticles can effectively promote the expression of CAMKK2 and AMPK proteins and inhibit the expression of m-TOR protein.
[0085] 11. Effects of Astragalus polysaccharide composite nanoparticles on the expression of autophagy-related proteins and Ca2+ / CAMKK2 / AMPK / mTORC1 signaling pathway-related proteins in tumor tissues of tumor-bearing mice
[0086] The expression of autophagy-related proteins and Ca2+ / CAMKK2 / AMPK / mTORC1 signaling pathway-related proteins was detected by Realtime method. The results are as follows Fig.13 As shown, Fig.13 a is the expression level of autophagy proteins in tumor tissues of each group. Fig.13 b is the expression level of pathway-related proteins in each group. Compared with the Model group, after the tumor-bearing mice were intervened by astragalus polysaccharide composite nanoparticles, the expression ratio of autophagy protein LC3BⅡ / Ⅰ in the tumor was increased, the expression ratio of P62 and Beclin-1 proteins was decreased, the expression ratio of AMPK and CAMKK2 was increased, and the expression ratio of signaling pathway-related mTOR protein was decreased.
[0087] 12. Effects of Astragalus polysaccharide composite nanoparticles on autophagy pathway-related indicators and autophagy-related protein mRNA expression levels in tumor tissues of tumor-bearing mice
[0088] The effects of APS on autophagy pathway-related indicators and autophagy-related protein mRNA expression levels were detected by RT-PCR. Fig.14 As shown in the figure, compared with the Model group, after using astragalus polysaccharide composite nanoparticles, astragalus polysaccharide composite nanoparticles can reduce the expression levels of P62, P70s6k, mTORC, and Beclin-1 protein mRNA, while the expression levels of CAMKK2 and AMPK protein mRNA are increased. Moreover, after astragalus polysaccharide composite nanoparticles are used in combination with Compound C, the promoting effect of astragalus polysaccharide composite nanoparticles on the mRNA related to the signaling pathway is significantly weakened compared with the use of astragalus polysaccharide composite nanoparticles alone.
[0089] 13. Effect of Astragalus Polysaccharide Composite Nanoparticles on Apoptosis of Tumor Tissue Cells in Tumor-bearing Mice
[0090] TUNEL staining was used to detect the effects of different drug groups on the apoptosis level of tumor tissue cells in tumor-bearing mice. Fig.15 As shown, Fig.15 a is a TUNEL staining fluorescence image, in which apoptotic tumor tissues show dense green fluorescence in the form of dots. Fig.15 b is the result of statistical analysis. Compared with the Model group, the apoptosis level in the APS group was significantly increased; the increase in the APS+5-FU group was more significant, and the apoptosis level in the Compound C group was significantly decreased. The combined use with astragalus polysaccharide composite nanoparticles significantly increased the apoptosis rate again. Compared with the Compound C group, the apoptosis level in the APS group was significantly increased, indicating that astragalus polysaccharide composite nanoparticles can effectively promote the apoptosis of tumor tissue cells in tumor-bearing mice.
[0091] It should be noted that, in this article, the terms "comprises", "includes" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device that includes a series of elements includes not only those elements, but also includes other elements that are not explicitly listed, or also includes elements inherent to such process, method, article or device; although the embodiments of the present application have been shown and described, it can be understood by those of ordinary skill in the art that various changes, modifications, substitutions and variations may be made to these embodiments without departing from the principles and spirit of the present application, and the scope of the present application is defined by the appended claims and their equivalents.
Claims
1. A method for preparing astragalus polysaccharide composite nanoparticles, characterized in that: The steps include: S1. Add dopamine hydrochloride to an ethanol aqueous solution, adjust the pH to 7.5-8.0 with an alkaline aqueous solution, stir and react at 30-40° C. for 10-15 hours. After the reaction is completed, centrifuge and remove the supernatant. Wash the precipitate with ethanol and water in turn, and dry to obtain polydopamine nanoparticles; S2, add polydopamine nanoparticles to ethanol, disperse evenly, add epichlorohydrin dropwise, react at 50-60°C for 4-6h, then add 3-5wt% carboxymethyl chitosan aqueous solution and triethylamine, heat to 70-80°C, react for 8-10h, after the reaction is completed, cool to room temperature, centrifuge, remove supernatant, wash the precipitate with ethanol and water in turn, and dry to obtain modified polydopamine nanoparticles; S3, dissolving astragalus polysaccharide in a phosphate buffer solution, adding modified polydopamine nanoparticles, stirring at room temperature for 24 hours, centrifuging, removing the supernatant, washing the precipitate with a phosphate buffer solution, and freeze-drying to obtain modified polydopamine nanoparticles loaded with astragalus polysaccharide; S4. Dissolve the modified polydopamine nanospheres loaded with astragalus polysaccharide in acetone, add enteric material and emulsifier, stir for 24 hours at room temperature, centrifuge, remove the supernatant, wash the precipitate with acetone, and freeze-dry to obtain composite nanoparticles.
2. The method for preparing astragalus polysaccharide composite nanoparticles according to claim 1, characterized in that: In step S1, the concentration of dopamine hydrochloride in the ethanol aqueous solution is 3-5 mg / mL; the mass ratio of ethanol to water is 1:4-6.
3. The method for preparing astragalus polysaccharide composite nanoparticles according to claim 1, characterized in that: The alkaline aqueous solution in step S1 is a 20-30 wt % ammonia aqueous solution.
4. The method for preparing astragalus polysaccharide composite nanoparticles according to claim 1, characterized in that: In step S2, the concentration of polydopamine nanospheres in ethanol is 80-100 mg / mL; the mass ratio of the polydopamine nanospheres, epichlorohydrin, carboxymethyl chitosan and triethylamine is 1:0.2-0.3:0.4-0.5:0.2-0.
3.
5. The method for preparing astragalus polysaccharide composite nanoparticles according to claim 1, characterized in that: In step S3, the concentration of astragalus polysaccharide in the phosphate buffer solution is 0.4-0.6 mg / mL; the concentration of modified polydopamine nanoparticles is 1-2 mg / mL; and the pH value of the phosphate buffer solution is 7.
4.
6. The method for preparing astragalus polysaccharide composite nanoparticles according to claim 1, characterized in that: In step S4, the concentration of the modified polydopamine nanoparticles loaded with astragalus polysaccharide in acetone is 50-60 mg / mL; the mass ratio of the modified polydopamine nanoparticles loaded with astragalus polysaccharide and the enteric material is 1:1.5-2; the amount of the emulsifier is 2-3% of the total mass of the modified polydopamine nanoparticles loaded with astragalus polysaccharide and the enteric material.
7. The method for preparing astragalus polysaccharide composite nanoparticles according to claim 6, characterized in that: The enteric material is composed of acrylic resin II and acrylic resin III in a mass ratio of 1:2-3; and the emulsifier is polyvinyl alcohol.
8. An astragalus polysaccharide composite nanoparticle, characterized in that: The astragalus polysaccharide composite nanoparticles are prepared by the preparation method of any one of claims 1 to 7.
9. Use of astragalus polysaccharide composite nanoparticles in the preparation of a drug for treating colorectal cancer, characterized in that: The drug comprises the astragalus polysaccharide composite nanoparticles according to claim 8.
10. Use of the astragalus polysaccharide composite nanoparticles according to claim 9 in the preparation of a drug for treating colorectal cancer, characterized in that: The drug inhibits the expression of P62, P70s6k, Beclin-1, and m-TOR proteins, promotes the expression of CAMKK2 and AMPK proteins, reduces the expression levels of P62, P70s6k, Beclin-1, and mTORC protein mRNA, and increases the expression levels of CAMKK2 and AMPK protein mRNA, thereby exerting an anti-colorectal cancer effect.
